ArticleESC heart failure2026
Epidemiology, clinical characteristics, and outcomes for heart failure with improved ejection fraction by chronological age.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHF incidence increases with age. Novel treatments have led to more patients recovering LVEF, now classified as HF with improved ejection fraction (HFimpEF). However, the age-related epidemiology and prognosis of HFimpEF remain unclear. METHODS AND
resultsWe identified adults ≥18 years with incident HFrEF (LVEF ≤40%) between 2013 and 2022 within Kaiser Permanente Northern California (KPNC), a healthcare delivery system serving 4.5 million members. HFimpEF was defined as baseline LVEF ≤40% with improvement to ≥40%. HFimpEF incidence was assessed by baseline age categories (<50, 50-64, 65-79, ≥80 years [yrs]). Rates of worsening HF (WHF) events (i.e. HF-related hospitalization, ED, or outpatient visits) were compared between HFimpEF and persistent HFrEF patients across age using Cox proportional hazards models adjusted for sex, race, and EF at the time of incident HFrEF, including evaluation of a potential interaction by age. DATA: Among 28 292 adults with incident HFrEF, 35% experienced HFimpEF, with lower rates at older ages: 43% (<50 yrs), 42% (50-64 yrs), 39% (65-79 yrs), and 21% (≥80 yrs) (P < .001 for trend). WHF incidence rates (per 100 person-years) increased with age: 10.6 [95% CI, 9.5-11.7] (<50 yrs), 14.5 [13.7-15.3] (50-64 yrs), 20.8 [20.0-21.6] (65-79 yrs), and 31.7 [29.9-33.5] (≥80 yrs). Patients with HFimpEF, compared to those with persistent HFrEF, had lower adjusted rates of WHF, a finding more prominent at lower ages (pinteraction by age <0.001).
conclusionsHFimpEF is common within a year of incident HFrEF, more prevalent in younger patients, and is associated with continued residual risk. Compared to persistent HFrEF, improvements in LVEF are associated with lower risk of WHF or death across the age spectrum. Additional research is needed to understand HF symptom burden and medical therapy use in this population to inform shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.